Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 11:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,107 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vein Disease Clear all
Completed No phase listed Observational Accepts healthy volunteers

Intravitreal Injection Site and Perceived Pain

NCT05640895
View directory record Official record
Conditions
Pain
Interventions
Intravitreal injection site
Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 100 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 7, 2026, 11:29 PM EDT
Recruiting No phase listed Observational

Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System

NCT07335341
View directory record Official record
Conditions
Venous Embolism of Lower Extremities (Diagnosis), Arterial Embolism and Thrombosis, Acute DVT of Lower Extremity, Chronic DVT of Lower Extremity, DVT, Deep Vein Thrombosis Leg, Thrombus in the Peripheral Venous Vasculature, Peripheral Arterial Disease, Acute Limb Ischemia, Lower Extremity Acute Limb Ischemia, LE ALI
Interventions
Liberant Thrombectomy System
Device
Lead sponsor
Medtronic Endovascular
Industry
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Naples, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 7, 2026, 11:29 PM EDT
Completed Phase 4 Interventional

Patient Comfort Following Intravitreal Injections Using Iheezo Versus Standard Anesthesia

NCT07779356
View directory record Official record
Conditions
Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion (RVO)
Interventions
Iheezo, Lidocaine pledget
Drug
Lead sponsor
Retina Consultants of Delmarva
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Easton, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 7, 2026, 11:29 PM EDT
Recruiting Not applicable Interventional

Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism

NCT07399977
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis
Interventions
MSK-ACCESS, ctDNA/VTE Risk Score:
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 7, 2026, 11:29 PM EDT
Completed Phase 3 Interventional Results available

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)

NCT00423319
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin, Apixaban, Enoxaparin-matching placebo, Apixaban-matching placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5,407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 7, 2026, 11:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study

NCT02390245
View directory record Official record
Conditions
Glaucoma, Glaucoma Suspect, Diabetic Retinopathy, Ocular Hypertension, Cataract, Branch Retinal Vein Occlusion, Branch Retinal Arterial Occlusion, Central Retinal Vein Occlusion, Central Retinal Artery Occlusion, Epi-retinal Membrane, Macular Degeneration, Drusen, Loss of Vision
Interventions
Free Eye Screenings, Enhanced Intervention, Usual Care
Other
Lead sponsor
Wills Eye
Other
Eligibility
40 Years and older
Enrollment
906 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 7, 2026, 11:29 PM EDT
Completed Phase 2 Interventional Results available

Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery

NCT03212365
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolus, Reconstructive Surgery
Interventions
Fixed dose, Variable dose
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Stanford, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 7, 2026, 11:29 PM EDT
Active, not recruiting Not applicable Interventional

Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC

NCT06811909
View directory record Official record
Conditions
Non-infected Venous Leg Ulcer, Venous Leg Ulcer, Venous Insufficiency, Venous Stasis, Venous Reflux
Interventions
BR-AC, Standard Care
Other
Lead sponsor
BioStem Technologies
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
22
States / cities
Guntersville, Alabama • Castro Valley, California • Glendale, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 7, 2026, 11:29 PM EDT
Suspended Not applicable Interventional

Glioblastoma Remote Monitoring and Care - Research Protocol

NCT06129760
View directory record Official record
Conditions
Glioblastoma, Venous Thromboembolism, Seizures
Interventions
Apple Watch
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 7, 2026, 11:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of the Toxic Metal Cadmium in the Mechanism Producing Infertility With a Varicocele

NCT00044369
View directory record Official record
Conditions
Varicocele, Male Infertility, Hypospermatogenesis, Non-Obstructive Azoospermia
Interventions
Varicocele repair
Procedure
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
21 Years to 55 Years · Male only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2005
U.S. locations
2
States / cities
Camden, New Jersey • Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2006 · Synced Oct 7, 2026, 11:29 PM EDT
Completed Not applicable Interventional Results available

V.A.C. VeraFlo™ Instillation Therapy vs V.A.C. Ulta™ Therapy on Biofilm in Chronically Infected Wounds

NCT02009501
View directory record Official record
Conditions
Lower Extremity Wound Infected, Venous Stasis Ulcers
Interventions
VAC VeraFlo with Dakins Instillation, VAC Ulta Therapy
Device
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 7, 2026, 11:29 PM EDT
Completed No phase listed Observational

Heparin Induced Thrombocytopenia: Pharmacoeconomics

NCT00456001
View directory record Official record
Conditions
Heparin Induced Thrombocytopenia (HIT)
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2009 · Synced Oct 7, 2026, 11:29 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence

NCT01072877
View directory record Official record
Conditions
Varicose Veins
Interventions
Polidocanol injectable foam (PEM), Placebo Vehicle
Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
20
States / cities
Laguna Hills, California • San Diego, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 7, 2026, 11:29 PM EDT
Terminated Phase 3 Interventional Results available

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

NCT03810313
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
30
States / cities
Phoenix, Arizona • La Jolla, California • Mountain View, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 7, 2026, 11:29 PM EDT
Not listed Phase 2 Interventional

Trial of Compassionate Use of hp802-247 to Treat Venous Leg Ulcers in Subjects Who Have Failed Multiple Other Healing Technologies

NCT01320605
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
Weekly wound spray with components 1 and 2 of the compound HP802-247
Biological
Lead sponsor
Atlantic Health System
Other
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Summit, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 22, 2011 · Synced Oct 7, 2026, 11:29 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

NCT01521559
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
Macular Laser Photocoagulation, Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
Procedure · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
45
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 7, 2026, 11:29 PM EDT
Not listed Phase 2Phase 3 Interventional

Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation

NCT00691470
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter, Venous Thromboembolic Disease, Myocardial Infarction, Cardiomyopathy
Interventions
ATI-5923, Coumadin (warfarin)
Drug
Lead sponsor
ARYx Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2010 · Synced Oct 7, 2026, 11:29 PM EDT
Withdrawn Phase 3 Interventional

Clinical Effectiveness of Topical Autologous Platelet Gel for the Treatment of Venous Ulcers

NCT00273234
View directory record Official record
Conditions
Venous Ulcer
Interventions
Autologous Platelet Gel (APG)
Procedure
Lead sponsor
National Healing Corporation
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
6
States / cities
St. Petersburg, Florida • Titusville, Florida • Newburyport, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2007 · Synced Oct 7, 2026, 11:29 PM EDT
Completed Not applicable Interventional

Discharge ALERT: Quality Improvement Initiative

NCT00853463
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Prophylaxis, Venous Thromboembolism, Prevention
Interventions
Alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2,515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
Long Beach, California • Orange, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2011 · Synced Oct 7, 2026, 11:29 PM EDT
Completed Phase 3 Interventional Results available

Safety of Dabigatran Etexilate in Blood Clot Prevention in Children

NCT02197416
View directory record Official record
Conditions
Venous Thromboembolism, Secondary Prevention
Interventions
dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
Up to 18 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
9
States / cities
Sacramento, California • Miami, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 7, 2026, 11:29 PM EDT
Completed Not applicable Interventional

Human Amniotic Membrane Grafting and Standard of Care Versus Standard of Care Alone in the Treatment of Venous Leg Ulcers

NCT01552447
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
EpiFix, Compression Therapy
Other
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Boca Raton, Florida • Framingham, Massachusetts • Tulsa, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Oct 7, 2026, 11:29 PM EDT
Not listed Phase 1Phase 2 Interventional

Mechanisms of Deep Vein Thrombosis (DVT) and Vein Wall Fibrosis

NCT04833764
View directory record Official record
Conditions
Post-thrombotic Syndrome, Deep Vein Thrombosis Leg
Interventions
Rosuvastatin
Drug
Lead sponsor
Khanh Nguyen
Federal
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 7, 2026, 11:29 PM EDT
Recruiting Early Phase 1 Interventional

Apixaban in Thrombocytopenia

NCT06886516
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism and Thrombosis, Thrombocytopenia, Recurrent Venous Thromboembolism
Interventions
Apixaban
Drug
Lead sponsor
Rushad Patell
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 7, 2026, 11:29 PM EDT
Completed No phase listed Observational

Outpatient Treatment of Low-Risk Venous Thromboembolism With Target Specific Anticoagulant

NCT02079584
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 7, 2026, 11:29 PM EDT